https://www.businesswire.com/news/home/20230209005014/en/Vivacelle-Bio%E2%80%99s-VBI-S-Phase-IIa-Clinical-Trial-Meets-Primary-and-Secondary-Endpoints-for-Treating-Hypovolemia-in-Septic-Shock-Patients

 KANSAS CITY, Mo.--(BUSINESS WIRE)--Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia. Severe septic shock patients experience a drastic drop in blood pressure that is associated with multiple organ failure causing patient death. While conventional fluids are effective for treating absolute hypovolemia, they are ineffective for treating relative hypovolemia, which is caused by excessive production of nitric oxide (NO) in septic shock. VBI-S, which is administered intravenously, reversibly absorbs NO, reducing the bioavailability of NO. This first of its kind approach reduces the bioavailability of NO without interfering with its production or essential cellular interactions. 

 www.businesswire.com 

Contacts

Harven DeShield, J.D., Ph.D., CEO
716-830-8932
harven@vivacellebio.com

Septic Shock Market is   Expected to Expand at a Healthy Growth Rate by (2022-2032), States   DelveInsight | Key Companies – Adrenomed AG, Vivacelle Bio, Inotrem - Digital   Journal

DelveInsight’s “Septic Shock Market Insights, Epidemiology,  and Market Forecast-2032″ report offers an in-depth understanding of the   Septic Shock,

www.digitaljournal.com